NSGl 533/l NSG533l Examl 2l –l (NEWl
2026/l 2027l Update)l Advancedl
Pharmacologyl Guide|l Questionsl &l
Answersl |l Gradel A|l 100%l Correctl
(Verifiedl Solutions)-l Wilkes
QUESTION
Clinicall Usel ofl Opioids
Answer:
Opioidl indications:l
ol Acutel severel painl (postoperative,l trauma)l
ol Cancer-relatedl painl
ol Selectl casesl ofl chronicl non-cancerl painl (whenl benefitsl outweighl risks)l
ol OUDl (Opioidl Usel Disorder):l Methadone,l buprenorphinel
Agentsl withl uniquel properties:l
ol Methadone:l NMDAl antagonist,l longl half-life,l QTcl riskl
ol Tramadol:l Inhibitsl reuptakel ofl serotonin/NE,l seizurel riskl
ol Fentanyl:l Preferredl inl renall impairment
Codeine:l Antitussive,l notl preferredl forl analgesia
QUESTION
Opioids:l Whatl Happensl atl thel Receptor
Answer:
Opioidsl bindl μl receptors,l whichl arel G-proteinl coupledl receptors.
Thisl leadsl to:
Inhibitionl ofl adenylatel cyclase
↓l cAMP
↓l calciuml influxl (presynaptic)
↑l potassiuml effluxl (postsynaptic)
Hyperpolarizationl ofl neurons
↓l neurotransmitterl releasel (substancel P,l glutamate)
Result:
,Decreasedl transmissionl ofl ascendingl painl signalsl Increasedl painl tolerancel Alteredl painl
perception
l Simplel Wayl tol Sayl Itl (Examl Version)
Opioidsl activatel μl receptorsl inl thel CNS,l inhibitingl ascendingl painl pathwaysl andl
alteringl thel perceptionl andl emotionall responsel tol pain.
QUESTION
Dosing,l Conversionl &l Riskl Thresholds
Answer:
MMEl (Morphinel Milligraml Equivalents):
ol Guidel forl safel opioidl prescribingl andl rotationol Cautionl atl >50l MME/day;l avoidl orl
justifyl >90l MME/day
Opioidl rotation:l Usel equianalgesicl tablesl carefully;l adjustl forl incompletel cross-tolerance.
Transdermall systemsl (e.g.,l fentanyll patch):l Requirel opioidl tolerancel priorl tol use.
QUESTION
Riskl Mitigationl Strategies
Answer:
Opioidl Riskl Toolsl (e.g.,l ORT)l tol assessl baselinel misusel risk.
Urinel drugl testing,l pilll counts,l PDMPl checksl (prescriptionl drugl monitoring).
Co-prescriptionl ofl naloxonel forl high-riskl patients.
REMSl programl trainingl forl extended-releasel opioids.
Taperingl strategiesl tol avoidl withdrawal.
QUESTION
Opioids:l Commonl Adversel Effects
Answer:
Think:l "Nol Poo,l Nol Air,l Nol Awake"
l 1.l Constipation
Decreasedl GIl motility
Increasedl waterl absorption
l 2.l Respiratoryl Depression
Decreasedl brainsteml sensitivityl tol CO₂
, l 3.l Sedation
CNSl depression
l 4.l Nausea/Vomiting
CTZl stimulation
l 5.l Pruritus
Histaminel releasel (especiallyl morphine)
l 6.l Urinaryl retention
l 7.l Miosisl (pinpointl pupils)
QUESTION
Opioids:l Howl tol Managel &l Preventl Adversel Effectsl ofl Constipation
Answer:
⚠l Tolerancel doesl NOTl develop.
Prevention:
Startl bowell regimenl atl initiation
Sennal ±l docusate
PEGl ifl needed
Naloxegoll orl methylnaltrexonel forl refractoryl cases
NEVERl waitl untill constipationl develops.
QUESTION
Opioids:l Howl tol Managel &l Preventl Adversel Effectsl ofl Respiratoryl depression
Answer:
Highl risk:
Elderly
Opioidl naïve
Renall failure
Concomitantl CNSl depressants
Management:
Holdl opioid
Naloxonel 0.4-2l mgl IV
Supportl airway
Prevention:
Startl low
Gol slow
, Monitorl RRl (<8-10l concerning)
QUESTION
Opioids:l Howl tol Managel &l Preventl Adversel Effectsl ofl Nausea
Answer:
Oftenl transient.
Management:
Antiemeticsl (ondansetron,l prochlorperazine)
Switchl opioidl ifl persistent
QUESTION
Opioids:l Doesl Tolerancel Developl tol Adversel Effects?
Answer:
Thisl isl al high-yieldl examl question.
✔l Tolerancel DOESl developl to:
Sedation
Nausea
Respiratoryl depressionl (partially)
l Tolerancel DOESl NOTl developl to:
Constipation
Miosis
Constipationl persistsl long-term.
QUESTION
Opioids:l Additionall Importantl Concepts
Answer:
Physicall Dependence
Withdrawall occursl ifl abruptlyl stopped.
Addiction
Psychologicall craving/compulsivel use.
Hyperalgesia
Paradoxicall increasedl painl sensitivityl withl chronicl opioidl use.
2026/l 2027l Update)l Advancedl
Pharmacologyl Guide|l Questionsl &l
Answersl |l Gradel A|l 100%l Correctl
(Verifiedl Solutions)-l Wilkes
QUESTION
Clinicall Usel ofl Opioids
Answer:
Opioidl indications:l
ol Acutel severel painl (postoperative,l trauma)l
ol Cancer-relatedl painl
ol Selectl casesl ofl chronicl non-cancerl painl (whenl benefitsl outweighl risks)l
ol OUDl (Opioidl Usel Disorder):l Methadone,l buprenorphinel
Agentsl withl uniquel properties:l
ol Methadone:l NMDAl antagonist,l longl half-life,l QTcl riskl
ol Tramadol:l Inhibitsl reuptakel ofl serotonin/NE,l seizurel riskl
ol Fentanyl:l Preferredl inl renall impairment
Codeine:l Antitussive,l notl preferredl forl analgesia
QUESTION
Opioids:l Whatl Happensl atl thel Receptor
Answer:
Opioidsl bindl μl receptors,l whichl arel G-proteinl coupledl receptors.
Thisl leadsl to:
Inhibitionl ofl adenylatel cyclase
↓l cAMP
↓l calciuml influxl (presynaptic)
↑l potassiuml effluxl (postsynaptic)
Hyperpolarizationl ofl neurons
↓l neurotransmitterl releasel (substancel P,l glutamate)
Result:
,Decreasedl transmissionl ofl ascendingl painl signalsl Increasedl painl tolerancel Alteredl painl
perception
l Simplel Wayl tol Sayl Itl (Examl Version)
Opioidsl activatel μl receptorsl inl thel CNS,l inhibitingl ascendingl painl pathwaysl andl
alteringl thel perceptionl andl emotionall responsel tol pain.
QUESTION
Dosing,l Conversionl &l Riskl Thresholds
Answer:
MMEl (Morphinel Milligraml Equivalents):
ol Guidel forl safel opioidl prescribingl andl rotationol Cautionl atl >50l MME/day;l avoidl orl
justifyl >90l MME/day
Opioidl rotation:l Usel equianalgesicl tablesl carefully;l adjustl forl incompletel cross-tolerance.
Transdermall systemsl (e.g.,l fentanyll patch):l Requirel opioidl tolerancel priorl tol use.
QUESTION
Riskl Mitigationl Strategies
Answer:
Opioidl Riskl Toolsl (e.g.,l ORT)l tol assessl baselinel misusel risk.
Urinel drugl testing,l pilll counts,l PDMPl checksl (prescriptionl drugl monitoring).
Co-prescriptionl ofl naloxonel forl high-riskl patients.
REMSl programl trainingl forl extended-releasel opioids.
Taperingl strategiesl tol avoidl withdrawal.
QUESTION
Opioids:l Commonl Adversel Effects
Answer:
Think:l "Nol Poo,l Nol Air,l Nol Awake"
l 1.l Constipation
Decreasedl GIl motility
Increasedl waterl absorption
l 2.l Respiratoryl Depression
Decreasedl brainsteml sensitivityl tol CO₂
, l 3.l Sedation
CNSl depression
l 4.l Nausea/Vomiting
CTZl stimulation
l 5.l Pruritus
Histaminel releasel (especiallyl morphine)
l 6.l Urinaryl retention
l 7.l Miosisl (pinpointl pupils)
QUESTION
Opioids:l Howl tol Managel &l Preventl Adversel Effectsl ofl Constipation
Answer:
⚠l Tolerancel doesl NOTl develop.
Prevention:
Startl bowell regimenl atl initiation
Sennal ±l docusate
PEGl ifl needed
Naloxegoll orl methylnaltrexonel forl refractoryl cases
NEVERl waitl untill constipationl develops.
QUESTION
Opioids:l Howl tol Managel &l Preventl Adversel Effectsl ofl Respiratoryl depression
Answer:
Highl risk:
Elderly
Opioidl naïve
Renall failure
Concomitantl CNSl depressants
Management:
Holdl opioid
Naloxonel 0.4-2l mgl IV
Supportl airway
Prevention:
Startl low
Gol slow
, Monitorl RRl (<8-10l concerning)
QUESTION
Opioids:l Howl tol Managel &l Preventl Adversel Effectsl ofl Nausea
Answer:
Oftenl transient.
Management:
Antiemeticsl (ondansetron,l prochlorperazine)
Switchl opioidl ifl persistent
QUESTION
Opioids:l Doesl Tolerancel Developl tol Adversel Effects?
Answer:
Thisl isl al high-yieldl examl question.
✔l Tolerancel DOESl developl to:
Sedation
Nausea
Respiratoryl depressionl (partially)
l Tolerancel DOESl NOTl developl to:
Constipation
Miosis
Constipationl persistsl long-term.
QUESTION
Opioids:l Additionall Importantl Concepts
Answer:
Physicall Dependence
Withdrawall occursl ifl abruptlyl stopped.
Addiction
Psychologicall craving/compulsivel use.
Hyperalgesia
Paradoxicall increasedl painl sensitivityl withl chronicl opioidl use.
